恒瑞医药与默沙东达成Lp(a)抑制剂独家许可协议

中国基金报
25 Mar

【导读】恒瑞医药与默沙东达成Lp(a)抑制剂独家许可协议中国基金报记者 卢鸰创新药龙头恒瑞医药又有出海大动作。恒瑞医药3月25日晚公告,公司与美国医药巨头默沙东达成协议,将恒瑞的脂蛋白(a)[Lp(a)]口服小分子项目(包括名为HRS-5346的先导化合物)有偿许可给默沙东,默沙东将获得HRS-5346在大中华区以外的全球范围内开发、生产和商业化的独家权利。恒瑞医药将收取2亿美元的首付款,并有资格...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10